Infographic | How often are drugmakers sharing clinical-trial data?

Infographic | How often are drugmakers sharing clinical-trial data?

The answer: it depends on what phase the trial is in.

Can marketing techniques save clinical trials?

Can marketing techniques save clinical trials?

No crucial area in pharma is more desperately in need of a fix — or more stubbornly resistant to change.

Study finds Repatha reduces risk of heart attack, stroke, but cost concerns remain

Study finds Repatha reduces risk of heart attack, stroke, but cost concerns remain

Amgen said it would offer payers a refund for patients who have a heart attack or stroke while taking the PCSK9 inhibitor.

For statin-intolerant patients, what's next?

For statin-intolerant patients, what's next?

Despite their blockbuster status and distinction as the world's most widely prescribed class of drugs, statins may not be the best option for all patients with elevated low density lipoprotein (LDL) cholesterol levels.

The 2017 pipeline report: What to know about next year's launches

The 2017 pipeline report: What to know about next year's launches

Here's a look at 100 experimental therapies in late-stage clinical trials.

Five things for pharma marketers to know: Monday, June 13, 2016

Five things for pharma marketers to know: Monday, June 13, 2016

A new Sanofi combination diabetes drug meets clinical trial targets; IBM partners with the American Diabetes Association; Dr. Reddy's to buy eight Teva drugs

Five things for pharma marketers to know: Thursday, May 19, 2016

Five things for pharma marketers to know: Thursday, May 19, 2016

Novartis plans new trials for Entresto; U.S. spending on mental health topped $201 billion in 2013; the FDA approves Roche's immunotherapy drug

Sensors, technology open the door to new era for clinical trials

Sensors, technology open the door to new era for clinical trials

Welcome to the mobile era for clinical trials, in which phone and tablet technology promise to upend a costly and unwieldy process.

Five things for pharma marketers to know: Wednesday, January 13, 2016

Five things for pharma marketers to know: Wednesday, January 13, 2016

Biden to lead "moonshot" to cure cancer; Pfizer/Allergan merger to create "best pipeline in the industry," CEO says; AMA invests in health tech startup

Five things for pharma marketers to know: Wednesday, December 30, 2015

Five things for pharma marketers to know: Wednesday, December 30, 2015

Twenty percent of publicly funded cancer clinical trials don't enroll enough patients; KaloBios files for bankruptcy; a new MS campaign in Australia uses bicycles

AstraZeneca to use mobile app in cancer trials

AstraZeneca to use mobile app in cancer trials

AstraZeneca plans to incorporate a mobile app that gathers information about side effects in three clinical trials studying an experimental combination therapy for ovarian cancer.

Five things for pharma marketers to know: Friday, November 20

Five things for pharma marketers to know: Friday, November 20

AstraZeneca and Sanofi to share compounds in rare agreement; FDA advisory committee votes against bladder cancer drug; Allergan may buyer in Pfizer deal

Five things for pharma marketers to know: Tuesday, November 3, 2015

Five things for pharma marketers to know: Tuesday, November 3, 2015

GSK partners with other drugmakers to bolster pipeline; Pfizer makes deal in South Africa for Prevnar 13; the FDA issues guidance on HIV biologic development

Five things for pharma marketers to know: Tuesday, October 20, 2015

Five things for pharma marketers to know: Tuesday, October 20, 2015

Therapy and low-dose drugs found to aid schizophrenia patients more than just antipsychotics; Clinton calls for investigations into drug price increases; Bayer issues RFP for AOR for consumer care brands

Five things for pharma marketers to know: Friday, October 16, 2015

Five things for pharma marketers to know: Friday, October 16, 2015

The NIH plans to fund fewer but more meaningful studies; the FDA asks for more data about AstraZeneca diabetes drug; payers continue to deny coverage for new hep.-C treatments